文献速递真菌感染

慢性肺曲霉病治疗反应监测:临床、肺功能与免疫学指标的作用

Monitoring treatment response in chronic pulmonary aspergillosis: role of clinical, spirometric and immunological markers.
PubMed 文献 · Clin Microbiol Infect · 2019-01-25

该研究纳入126例未治疗过的慢性肺曲霉病患者,接受唑类抗真菌治疗6个月,评估血清烟曲霉特异性IgG、半乳甘露聚糖、体重和肺功能对治疗反应的监测价值。结果显示特异性IgG和半乳甘露聚糖下降在有利与不利反应组间无显著差异,肺功能变化亦无差异;不利反应组体重显著下降。

要点

  • 血清烟曲霉特异性IgG和半乳甘露聚糖在治疗6个月后下降不一致,不推荐作为CPA治疗反应监测指标。
  • 肺功能(FEV1)在治疗6个月后变化不大,监测价值有限。
  • 体重增加见于治疗反应有利者,体重下降提示反应不利。

核心结论

  • 血清烟曲霉特异性IgG和血清半乳甘露聚糖在治疗后下降不一致,可能不是监测CPA治疗反应的有用指标。
  • 肺功能在治疗后变化不大,体重增加见于治疗反应有利者。

研究设计与样本

  • 研究纳入126例连续未治疗过的慢性肺曲霉病患者,男性占53.2%(67/126),平均年龄42.3±14.7岁。

主要发现

  • 治疗6个月后,有利与不利反应组血清烟曲霉特异性IgG下降相似(平均±SD,-26.3±45.5 mgA/L vs. -3.4±65.6 mgA/L;p 0.20)。
  • 治疗6个月后血清半乳甘露聚糖变化无显著差异(有利 vs. 不利:平均±SD,-0.11±2.8 vs. -0.62±2;p 0.92)。
  • 治疗6个月后FEV1变化无显著差异(有利 vs. 不利:平均±SD,24±250 mL vs. -62±154 mL;p 0.19)。
  • 不利反应组体重显著下降(平均±SD,-2.5±4.5 kg)。

临床怎么用

  • 临床监测CPA治疗反应时,不应依赖血清烟曲霉特异性IgG或半乳甘露聚糖的下降。
  • 体重变化可作为辅助判断治疗反应的指标,体重增加提示反应有利,体重下降提示反应不利。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The treatment response in chronic pulmonary aspergillosis (CPA) is usually assessed based on the improvement in clinical and imaging findings. Herein, we evaluate serum Aspergillus fumigatus-specific IgG, serum galactomannan, weight change, and lung function for assessing treatment response in subjects with CPA. METHODS: We categorized treatment response as favourable (improved or stable clinical response with radiologically improved or stable disease) or unfavourable (worsening of symptoms or radiological progression) after 6 months of treatment with antifungal azoles. We measured A. fumigatus-specific IgG, serum galactomannan, weight, and lung function at baseline, 3 months, and 6 months in those with favourable and unfavourable treatment response. RESULTS: One hundred and twenty-six consecutive treatment-naïve subjects (53.2% (67/126) males; mean ± SD age, 42.3 ± 14.7 years) with CPA were included. One hundred and six and 20 were classified as having favourable and unfavourable response, respectively. After 6 months of treatment, the decline in serum A. fumigatus-specific IgG (n = 119) was similar in those with favourable or unfavourable response (mean ± SD, -26.3 ± 45.5 mgA/L vs. -3.4 ± 65.6 mgA/L; p 0.20). There was no significant change in the serum galactomannan (favourable vs. unfavourable: mean ± SD, -0.11 ± 2.8 vs. -0.62 ± 2; p 0.92) or FEV1 (favourable vs. unfavourable: mean ± SD, 24 ± 250 mL vs. -62 ± 154 mL; p 0.19) after 6 months of treatment. There was significant loss of weight (mean ± SD, -2.5 ± 4.5 kg) in subjects with unfavourable response. CONCLUSION: Serum A. fumigatus-specific IgG and serum galactomannan inconsistently decrease following treatment and may not be useful indicators for monitoring treatment response in CPA. Similarly, there is little change in pulmonary function following treatment. A gain in body weight is seen in those with favourable response.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Sehgal IS, Dhooria S, Choudhary H, et al. Monitoring treatment response in chronic pulmonary aspergillosis: role of clinical, spirometric and immunological markers. Clin Microbiol Infect. 2019. PMID: 30685498. doi:10.1016/j.cmi.2019.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。